Predicting responsiveness to GLP-1 pathway drugs using real-world data
2024

Predicting Responsiveness to GLP-1 Pathway Drugs

Sample size: 7856 publication 10 minutes Evidence: moderate

Author Information

Author(s): Zhu Xiaodong, Fowler Michael J., Wells Quinn S., Stafford John M., Gannon Maureen

Primary Institution: Vanderbilt University Medical Center

Hypothesis

Can a predictive model be developed to identify which patients will respond best to GLP-1 pathway medications for Type 2 diabetes?

Conclusion

The study found that a predictive model based on real-world data can help identify patients who are likely to benefit from GLP-1 medications.

Supporting Evidence

  • Higher pre-treatment HbA1C is a dominant feature for predicting better response to GLP-1 medications.
  • Simultaneous use of NSAIDs was associated with better responsiveness in women under 40.
  • Combining GLP-1 medications with thiazolidinediones or sulfonylureas may not provide additional benefits.

Takeaway

This study helps doctors figure out which diabetes patients will do better with certain medications by looking at their health records.

Methodology

The study analyzed electronic health records of 7856 subjects with Type 2 diabetes treated with GLP-1 medications from 2003 to 2019, comparing different predictive models.

Potential Biases

The dataset may have inherent biases due to the limited number of standard lab tests commonly ordered.

Limitations

The study was conducted at a single academic medical center, which may limit the generalizability of the findings.

Participant Demographics

The cohort included 7856 subjects, with a mean age of 57.3 years, 49.78% female, and diverse racial backgrounds.

Statistical Information

P-Value

0.008

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/s12902-024-01798-9

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication